|
|
|
| home > ebr > spring 2003 > from pipe dream to pipeline dream: personalised medicine takes off |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review
|
| Three years ago, at the height of biotech's popularity on Wall Street, the promise of personalised medicine was just emerging. In 2000, only a handful of companies - most notably the then leader of the genomics pack, Millennium Pharmaceuticals - billed themselves as participants in the business of personalised medicine. Since that time, the promise has evolved into a reality with the advent of Genentech's Herceptin and Novartis' Gleevec - both targeted cancer therapies that work very well for patients with the right molecular profile. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
5th Annual BioPharma Asia Convention 2012
19-22 March 2012, Marina Bay Sands, Singapore
BioPharma Asia Convention is the only event that brings together senior level executives from global and regional pharma companies, biotechs, CMOs, CROs, academic institutions, investors and all other industrial stakeholders to assess the latest industrial trends, partnership models and solutions in Asia.
More info >> |
|
 |
News and Press Releases |
 |
Firstan Ltd are first to achieve the new Pharmaceutical PS9000:2011 quality standard
Firstan Ltd, the UK’s leading independently owned Pharmaceutical and Food Carton producer have become the first UK Packaging company to achieve the new Pharmaceutical PS9000:2011 quality standard for its Healthcare Division. This standard was published in September 2011 in consultation with industry suppliers, pharmaceutical companies and other stakeholder organisations. Firstan have held the Pharmaceutical accreditation for almost 20 years.
More info >> |
|
|
